HMAs Underutilized in Older, Female and Non-White Patients with MDS
CURE,
Hypomethylating agents are underutilized, particularly among older, female and non-White patients with MDS: © stock.adobe.com.
Disparities in Care for High-Risk Blood Disorders
U.S.Pharmacist,
Cleveland—Myelodysplastic syndrome (MDS), a group of blood cancers in which the bone marrow does not produce enough healthy…
Few With Myelodysplastic Syndromes Receive Hypomethylating Agents
Neurology Advisor ,
HealthDay News — Few patients with myelodysplastic syndromes (MDS) receive treatment with hypomethylating agents (HMAs), with…
Data Show Disparities in HMA Use Among Myelodysplastic Syndrome Populations
Cancer Network,
"Our work highlights the need to shift our approach beyond disease-related factors to recognize and narrow disparities in HMA…